To listen to the live audio webcast, please register using the weblink above, which has also been posted to the Company's "Investor Info" section at https://www.auroramj.com/investors/ under "Events". A replay of the presentation will be available using the same link for approximately 90 days. About Aurora Cannabis Inc. Canada's Largest Medical Cannabis Company to Discuss Strategy, Industry Trends, and Long-Term Growth Outlook EDMONTON, ALBERTA, Aug. 7, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) ...

EDMONTON, AB, March 31, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, has been named an honouree on the Globe & Mail's 2025 Report on Business, Women Lead Here list. This annual editorial benchmark recognizes the top publicly traded Canadian companies with the highest gender diversity at the executive level. Canada's Largest Medical Cannabis Company is an Honouree in The Globe and Mail's 2025 Report on Business Magazine's sixth ...

Core Insights - Aurora Cannabis Inc. is participating as a leader in the inaugural Global Cannabis Regulatory Summit (GCRS) in Washington, D.C. on March 26-27, 2025, highlighting its role in advocating for policy reform in the cannabis industry [1][2] Company Overview - Aurora Cannabis is a leading global medical cannabis company based in Canada, serving both medical and consumer markets across Canada, Europe, Australia, and New Zealand [3] - The company offers a diverse portfolio of adult-use brands including Drift, San Rafael '71, Daily Special, Tasty's, Being, and Greybeard, as well as medical cannabis brands such as MedReleaf, CanniMed, Aurora, and Whistler Medical Marijuana Co. [3] - Aurora also holds a controlling interest in Bevo Farms Ltd., a major supplier of propagated agricultural plants in North America [3] Industry Engagement - The GCRS will facilitate discussions among regulators, members of Congress, international policy experts, and cannabis industry executives to shape the future of the global cannabis industry [2][3] - Aurora's participation in panel discussions aims to enhance understanding of the distinctions between medical and adult-use cannabis, informed by international political and regulatory consensus [3]